Discover 680 paid clinical trials in Killeen, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 680
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
for
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Location: Austin TX, San Antonio TX, Sugar Land TX,
Sponsor: Alkermes, Inc.
Sex: All
Age: 18 - 70
Code: NCT06767683
Phase2, Phase3, Recruiting
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
for
Narcolepsy Type 2
Location: Austin TX, San Antonio TX, El Paso TX,
Sponsor: Takeda
Sex: All
Age: 18 - 70
Code: NCT06952699
Phase2, Recruiting
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
for
Schizophrenia
Location: Austin TX, Richardson TX, Oklahoma City OK,
Sponsor: Reviva Pharmaceuticals
Sex: All
Age: 18 - 65
Code: NCT05184335
Phase3, Recruiting
Randomized Withdrawal Study in Patients With Schizophrenia
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
for
Relapsing Multiple Sclerosis
Location: Austin TX, Fort Worth TX, Dallas TX, Plano TX,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 40 - 70
Code: NCT06846281
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
New
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
for
Type 2 Diabetes
Location: Austin TX, Clearwater FL, Riverview FL,
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT07754461
Phase3, Recruiting
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
for
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Location: Austin TX, Sandy City UT, Detroit MI, Morehead City NC,
Sponsor: DreaMed Diabetes
Sex: All
Age: 18 - 70+
Code: NCT07599982
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Austin TX, Fort Worth TX, San Antonio TX, Tyler TX,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06136559
Phase3, Recruiting
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
for
Low Grade Serous Ovarian Cancer
Location: Austin TX, Fort Worth TX, San Antonio TX,
Sponsor: Verastem, Inc.
Sex: Female
Age: 18+
Code: NCT06072781
Phase3, Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
for
Melanoma
Location: Austin TX, Fort Worth TX, Bedford TX, Dallas TX,
Location: Austin TX, Fort Worth TX, Dallas TX, Abilene TX,
Sponsor: Genmab
Sex: All
Age: 18+
Code: NCT05579366
Phase1, Phase2, Recruiting
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
for
Lung Neoplasm Malignant
Location: Austin TX, Tyler TX, Daphne AL, Lone Tree CO,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06788912
Phase2, Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
for
Ovarian Cancer, Fallopian Tube Cancer,
Location: Austin TX, Fort Worth TX, San Antonio TX, Webster TX,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT06824467
Phase3, Recruiting
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
for
Stage III Ovarian Cancer, Stage IV Ovarian Cancer,
Location: Austin TX, Houston TX, New Orleans LA, Overland Park KS,
Sponsor: GOG Foundation
Sex: Female
Age: 18+
Code: NCT05659381
Phase3, Recruiting
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer